Stick2PrEP Cisgender Women and Trans Individuals (NCT05165745)
Stick2PrEP Women/Trans Individuals: Increasing Pre-Exposure Prophylaxis (PrEP) Uptake, Adherence, and Retention in Care, and Understanding PrEP Preferences Among Predominantly Black and Latinx Cisgender Women and Transgender Individuals
🩺 Plain-English Summary (8th-Grade Level)
Taking a daily anti-HIV pill can protect people from HIV infection. This is called preexposure prophylaxis \[PrEP\]. Many cisgender women and trans individuals do not know this medication is available; others struggle to take the pill every day. It is important to understand attitudes and preferences about HIV prevention options, especially as new options become available. This study plans to evaluate preferences over time among cisgender women and trans individuals who are taking medication to prevent HIV, and among cisgender women and trans individuals who are not taking medication but are at risk of HIV. The investigators enroll up to 175 participants who visit the HIV prevention clinic, and the investigators will ask participants to complete questionnaires at regular follow up visits and between visits. This study may help the investigators understand how best to prevent HIV among people at risk.
Who can join: Review the eligibility criteria below.
Location: Columbia University Medical Center — New York, New York
Age range: 18 Years
🧪 Interventions in This Study
- Individualized Feedback (BEHAVIORAL)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Columbia University Medical Center — New York, New York
📞 Contact the Study Coordinator
Phone: (212) 305-2201
Email: dat2132@cumc.columbia.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in HIV Prevention
- PrEP-Pod-IVR (TDF-FTC/Placebo IVR 28 Day Crossover Study) — Galveston, Texas
- Integrated HIV Prevention and HCV Care for PWID — Miami, Florida
- Clinic-based HIV Identification and Prevention Project Using Electronic Resources — Baltimore, Maryland
- Digital Limited Interaction Efficacy Trial of LifeSkills Mobile to Reduce HIV Incidence in YTW — Los Angeles, California
- Examining Migration, Social Bonds, Transnationalism, and HIV Prevention Pathways Among African Immigrants. — Buffalo, New York
- PrEP & Soccer: A Program for Pharmacy Chains to Increase PrEP Awareness and Access Among Men — Miami, Florida
Explore by condition: All HIV Prevention clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.